Search

Your search keyword '"Claudia Traidl‐Hoffmann"' showing total 11 results
Start Over Author "Claudia Traidl‐Hoffmann" Journal allergy
11 results on '"Claudia Traidl‐Hoffmann"'

2. Is exposure to pollen a risk factor for moderate and severe asthma exacerbations?

Author

Isabella Annesi‐Maesano, Lorenzo Cecchi, Benedetta Biagioni, Kian Fan Chung, Bernard Clot, Martine Collaud Coen, Gennaro D'Amato, Athanasios Damialis, Javier Dominguez‐Ortega, Carmen Galàn, Stefanie Gilles, Stephen Holgate, Mohamed Jeebhay, Stelios Kazadzis, Nikolaos G. Papadopoulos, Santiago Quirce, Joaquin Sastre, Fiona Tummon, Claudia Traidl‐Hoffmann, Jolanta Walusiak‐Skorupa, Pablo Alonso‐Coello, Carlos Canelo‐Aybar, Yahveth Cantero‐Fortiz, David Rigau, Josefina Salazar, Francisca Verdugo‐Paiva, Marek Jutel, Cezmi A. Akdis, and Ioana Agache

Subjects
Immunology, Immunology and Allergy, ddc:610
Abstract

Background Limited number of studies have focused on the impact of pollen exposure on asthma. As a part of the EAACI Guidelines on Environment Science, this first systematic review on the relationship of pollen exposure to asthma exacerbations aimed to bridge this knowledge gap in view of implementing recommendations of prevention. Methods We searched electronic iPubMed, Embase, and Web of Science databases using a set of MeSH terms and related synonyms and identified 73 eligible studies that were included for systemic review. When possible, meta-analyses were conducted. Results Overall meta-analysis suggests that outdoor pollen exposure may have an effect on asthma exacerbation but caution is needed due to the low number of studies and their heterogeneity. The strongest associations were found between asthma attacks, asthma-related ED admissions or hospitalizations and an increase of grass pollen concentration in the previous 2 days overall in children aged less than 18 years of age. Tree pollen may increase asthma-related ED visits or admissions lagged up to 7 days overall in individuals younger than 18 years. Rare data show that among subjects under 18 years of age an exposure to grass pollen lagged up to 3 days may lower lung function. Conclusions Further research considering effect modifiers of pollen sensitization, hay fever, asthma, air pollution, green spaces and pre-existing medications is urgently warranted to better evaluate the impacts of pollen on asthma exacerbation. Preventive measures in relation to pollen exposure should be integrated in asthma control as pollen increase continues due to climate change.

Published
2023
Full Text
View/download PDF

3. A new era of atopic eczema research: Advances and highlights

Author

Andreas B Weins, Claudia Traidl-Hoffmann, Matthias Reiger, and Claudia Hülpüsch

Subjects
Atopic Dermatitis, Biomarkers, Personalized Medicine, Therapy, Staphylococcus aureus, business.industry, Microbiota, Immunology, Atopic dermatitis, Disease, Filaggrin Proteins, Administration, Cutaneous, medicine.disease, Precision medicine, Dermatitis, Atopic, Type 2 immune response, medicine, Dysbiosis, Humans, Immunology and Allergy, ddc:610, Microbiome, Personalized medicine, business, Filaggrin
Abstract

Atopic eczema (AE) is an inflammatory skin disease with involvement of genetic, immunological, and environmental factors. One hallmark of AE is a skin barrier disruption on multiple, highly interconnected levels: filaggrin mutations, increased skin pH, and a microbiome dysbiosis towards Staphylococcus aureus overgrowth are observed in addition to an abnormal type 2 immune response. Extrinsic factors seem to play a major role in the development of AE. As AE is a first step in the atopic march, its prevention and appropriate treatment is essential. Although standard therapy remains topical treatment, powerful systemic treatment options emerged in the last years. However, thorough endotyping of the individual patients is still required for ideal precision medicine approaches in the future. Therefore, novel microbial and immunological biomarkers were described recently for the prediction of disease development and treatment response. This review summarizes the current state of the art in AE research.

Published
2021
Full Text
View/download PDF

4. COVID-19 pandemic

Author

W. J. Fokkens, Jürgen Schwarze, Cezmi A. Akdis, J Mullol, W. Czarlewski, Claudia Traidl-Hoffmann, Claus Bachert, D. Larenas-Linnemann, Tomas Chivato, M. Gotua, Mateo Bonini, Ludger Klimek, Vincenzo Patella, A. A. Cruz, Stephanie Dramburg, Kari C. Nadeau, H W Fritsch, K. Ohta, Thomas Eiwegger, Robert M. Naclerio, Antti Lauerma, A. Yorgancioglu, Aslı Gelincik, Piotr Kuna, Oliver Pfaar, Carmen Riggioni, Violeta Kvedariene, Markus Ollert, Sinthia Bosnic-Anticevich, V. Cardona, S. Del Giacco, Sanna Toppila-Salmi, Helen A. Brough, Heimo Breiteneder, Valérie Hox, B. Samolinski, Zuzana Diamant, G.W. Canonica, Lihong Zhang, María José Torres, Y. Okamoto, Liam O'Mahony, Radosław Gawlik, Jolanta Walusiak-Skorupa, Sharon Chinthrajah, Winfried Rief, T. Haatela, M. Morais-Almeida, Ioana Agache, Manfred Schedlowski, I Skypala, R. Brehler, D. Y. Wang, João Fonseca, I. J. Ansotegui, Robyn E O'Hehir, Oscar Palomares, Charlotte G. Mortz, J. C. Ivancevich, C. Suppli Ulrik, M. T. Ventura, P M Matricardi, S Untersmayr, Gabrielle L. Onorato, Amir Hamzah Abdul Latiff, Frederico S. Regateiro, Vanitha Sampath, Arũnas Valiulis, Marek Jutel, Luisa Brussino, Pedro Carreiro-Martins, Jean Bousquet, Nikolaos G. Papadopoulos, A. Bedbrook, Torsten Zuberbier, Karin Hoffmann-Sommergruber, Edward F. Knol, Ear, Nose and Throat, AII - Inflammatory diseases, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service d'oto-rhino-laryngologie, Philipps Universität Marburg = Philipps University of Marburg, Allergologie, Stimm und Sprachstörungen [Wiesbaden, Germany], Zentrum für Rhinologie und Allergologie [Wiesbaden, Germany], University of Wrocław [Poland] (UWr), ALL-MED, Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Medizinische Universität Wien = Medical University of Vienna, Stanford University, Skane University Hospital [Malmo], Lund University [Lund], Charles University [Prague] (CU), University Medical Center Groningen [Groningen] (UMCG), Univ Toronto, Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Mol Med, Toronto, ON M5G 0A4, Canada, The Hospital for sick children [Toronto] (SickKids), University of Toronto, Amsterdam UMC - Amsterdam University Medical Center, Alfred Health, Victoria University [Melbourne], University College Cork (UCC), Sean N. Parker Center for Allergy and Asthma Research [Stanford], Stanford Medicine, Stanford University-Stanford University, University Clinics of Essen, University of Essen, Allergy Unit [Malaga, Spain] (National Network ARADyAL), Hospital Regional Universitario de Málaga = Regional University Hospital of Malaga [Spain], Helmholtz Zentrum München = German Research Center for Environmental Health, University Hospital Augsburg, National University of Singapore (NUS), Beijing Tongren Hospital, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, University Hospital Münster - Universitaetsklinikum Muenster [Germany] (UKM), Evelina London Children's Hospital, King‘s College London, CEU-San Pablo University and HM-Hospitals School of Medicine, University of Cagliari, Medical University of Silesia (SUM), Istanbul University, Cliniques Universitaires Saint-Luc [Bruxelles], University Medical Center [Utrecht], Helsinki University Central Hospital, University of Helsinki, Odense University Hospital (OUH), Luxembourg Institute of Health (LIH), Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Hospital Sant Joan de Déu [Barcelona], Institut de Recerca Pediàtrica Hospital Sant Joan de Déu [Barcelona, Spain], University of Edinburgh, NHS Foundation Trust [London], The Royal Marsden, Nofer Institute of Occupational Medicine (NIOM), Hospital Quirónsalud Bizkaia [Bilbao], Ghent University Hospital, Sun Yat-Sen University [Guangzhou] (SYSU), Karolinska Institutet [Stockholm], Woolcock Institute of Medical Research [Sydney], The University of Sydney, University of Turin, Mauriziano Umberto I Hospital, Humanitas University [Milan] (Hunimed), Vall d'Hebron University Hospital [Barcelona], Hospital de Dona Estefania, NOVA Medical School - Faculdade de Ciências Médicas (NMS), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Federal University of Bahia School of Medicine, Global Alliance Against Chronic Respiratory Diseases (GARD-WHO), Medical Consulting Czarlewski, Faculdade de Medicina da Universidade do Porto (FMUP), Universidade do Porto = University of Porto, MEDIDA, Lda, David Tvildiani Medical University (DTMU), Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Barlicki University Hospital, Vilnius University [Vilnius], Hospital Medica Sur [Mexico City, Mexico], Pantai Hospital [Kuala Lumpur], Hospital CUF Descobertas, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), CIBER de Epidemiología y Salud Pública (CIBERESP), Johns Hopkins University School of Medicine [Baltimore], Fukujuji Hospital, Tokyo National Hospital, Chiba Rosai Hospital, Chiba University Hospital, Royal Manchester Children's Hospital, University of Manchester [Manchester], General Children's Hospital of Athens P & A Kyriakou, 'Santa Maria della Speranza' Hospital, Centro Hospitalar e Universitário [Coimbra], Coimbra Institute for Clinical and Biomedical Research [Coimbra, Portugal] (iCBR - Faculty of Medicine), University of Coimbra [Portugal] (UC), Medical University of Warsaw - Poland, Hvidovre Hospital, University of Copenhagen = Københavns Universitet (UCPH), Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Manisa Celal Bayar University, Transilvania University of Brasov, Salvy-Córdoba, Nathalie, Department of Dermatology, Allergology and Venereology, and HUS Inflammation Center

Subjects
0301 basic medicine, viruses, Eaaci Position Paper, Medizin, Cochrane Library, GUIDELINES, FOOD ALLERGY, allergen immunotherapy, allergy clinic, anaphylaxis, asthma, clinical trials, COVID-19, Position Paper, psychological impact, SARS-CoV-2, Allergists, Health Personnel, Humans, Hypersensitivity, Information Technology, Patient Care Team, Triage, SARS‐CoV‐2, DESENSITIZATION, 0302 clinical medicine, MESH: Patient Care Team, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, HDE ALER, Pandemic, Health care, Immunology and Allergy, ATOPIC-DERMATITIS, MESH: COVID-19, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, allergen immunotherapy (AIT), virus diseases, DRUG HYPERSENSITIVITY REACTIONS, 3. Good health, INFECTIONS, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Triage, [SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology, Allergen immunotherapy, medicine.medical_specialty, MESH: Information Technology, MESH: Hypersensitivity, Immunology, education, MEDLINE, DIAGNOSIS, psychological COVID, 03 medical and health sciences, MESH: Allergists, COVID‐19, medicine, MESH: SARS-CoV-2, ddc:610, RHINOSINUSITIS, MESH: Humans, business.industry, Clinical trial, Coronavirus, EXACERBATIONS, 030104 developmental biology, 030228 respiratory system, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Family medicine, 3121 General medicine, internal medicine and other clinical medicine, Position paper, MESH: Health Personnel, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business
Abstract

BackgroundThe Coronavirus disease 2019 (COVID‐19) has evolved as a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS‐CoV‐)2. Allergists and other health care providers (HCPs) in the field of allergies and associated airway diseases are in the front line, taking care of patients potentially infected with SARS‐CoV‐2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics.MethodThe scientific information on COVID‐19 was analyzed by a literature search in Medline, Pubmed, national and international guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library and the Internet.ResultsBased on diagnostic and treatment standards developed by EAACI, on international information regarding COVID‐19, on guidelines of the World Health Organization (WHO) and other international organizations as well as on previous experience, a panel of experts including clinicians, psychologists, IT experts and basic scientists along with EAACI and the “Allergic Rhinitis and its Impact on Asthma (ARIA)” inititiative have developed recommendations for the optimal management of allergy clinics during the current COVID‐19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies.ConclusionsThis international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients whilst ensuring necessary safety in the current COVID‐19 pandemic.

Published
2021
Full Text
View/download PDF

5. Distribution of ACE2, CD147, CD26, and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors

Author

Hideaki Morita, Ge Tan, Shuo Li, Can Altunbulakli, Damir Zhakparov, Mei Ding, Yaqi Peng, Avidan U. Neumann, Urszula Radzikowska, Liam O'Mahony, Paulina Wawrzyniak, Matthias Reiger, Claudia Traidl-Hoffmann, Cezmi A. Akdis, Kari C. Nadeau, Milena Sokolowska, Ming Wang, Nonhlanhla Lunjani, University of Zurich, and Sokolowska, Milena

Subjects
0301 basic medicine, Immunology, 610 Medicine & health, Peripheral blood mononuclear cell, 03 medical and health sciences, 0302 clinical medicine, Immune system, 10183 Swiss Institute of Allergy and Asthma Research, medicine, Immunology and Allergy, ddc:610, Receptor, Asthma, 2403 Immunology, COPD, medicine.diagnostic_test, business.industry, Atopic dermatitis, medicine.disease, 030104 developmental biology, Bronchoalveolar lavage, 030228 respiratory system, 2723 Immunology and Allergy, business, CD8
Abstract

Background: Morbidity and mortality from COVID-19 caused by novel coronavirus SARS-CoV-2 is accelerating worldwide, and novel clinical presentations of COVID-19 are often reported. The range of human cells and tissues targeted by SARS-CoV-2, its potential receptors and associated regulating factors are still largely unknown. The aim of our study was to analyze the expression of known and potential SARS-CoV-2 receptors and related molecules in the extensive collection of primary human cells and tissues from healthy subjects of different age and from patients with risk factors and known comorbidities of COVID-19. Methods: We performed RNA sequencing and explored available RNA-Seq databases to study gene expression and co-expression of ACE2, CD147 (BSG), and CD26 (DPP4) and their direct and indirect molecular partners in primary human bronchial epithelial cells, bronchial and skin biopsies, bronchoalveolar lavage fluid, whole blood, peripheral blood mononuclear cells (PBMCs), monocytes, neutrophils, DCs, NK cells, ILC1, ILC2, ILC3, CD4+ and CD8+ T cells, B cells, and plasmablasts. We analyzed the material from healthy children and adults, and from adults in relation to their disease or COVID-19 risk factor status. Results: ACE2 and TMPRSS2 were coexpressed at the epithelial sites of the lung and skin, whereas CD147 (BSG), cyclophilins (PPIA andPPIB), CD26 (DPP4), and related molecules were expressed in both epithelium and in immune cells. We also observed a distinct age-related expression profile of these genes in the PBMCs and T cells from healthy children and adults. Asthma, COPD, hypertension, smoking, obesity, and male gender status generally led to the higher expression of ACE2- and CD147-related genes in the bronchial biopsy, BAL, or blood. Additionally, CD147-related genes correlated positively with age and BMI. Interestingly, we also observed higher expression of CD147-related genes in the lesional skin of patients with atopic dermatitis. Conclusions: Our data suggest different receptor repertoire potentially involved in the SARS-CoV-2 infection at the epithelial barriers and in the immune cells. Altered expression of these receptors related to age, gender, obesity and smoking, as well as with the disease status, might contribute to COVID-19 morbidity and severity patterns. Keywords: COPD; COVID-19; COVID-19 children; SARS receptor; asthma; hypertension; obesity.

Published
2020
Full Text
View/download PDF

6. State‐of‐the‐art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI)

Author

Claudia Traidl-Hoffmann, Oscar Palomares, Sergio Bonini, Claudio Rhyner, Ralph Mösges, Philippe Moingeon, Franziska Roth-Walter, Robyn E O Hehir, Ludger Klimek, Vera Mahler, Carsten B. Schmidt-Weber, Lars Jacobsen, Michael Rudenko, Erika Jensen-Jarolim, Johannes Savolainen, Marek Jutel, Oliver Pfaar, Martin F. Bachmann, Harald Renz, Thomas M. Kündig, University of Zurich, and Jensen‐Jarolim, E

Subjects
Allergen immunotherapy, Allergy, medicine.medical_treatment, Immunology, Monophosphoryl Lipid A, 610 Medicine & health, Adjuvants, allergen immunotherapy, aluminium, microcrystalline tyrosine, monophosphoryl-lipid A (MPLA), medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, Allergen, Immune system, Adjuvants, Immunologic, 10183 Swiss Institute of Allergy and Asthma Research, Immunity, Hypersensitivity, medicine, Humans, Immunology and Allergy, Allergen Immunotherapy, Aluminium, Microcrystalline Tyrosine, Monophosphoryl Lipid A (mpla), ddc:610, 2403 Immunology, business.industry, Immunogenicity, 10177 Dermatology Clinic, Allergens, medicine.disease, Europe, 030228 respiratory system, Desensitization, Immunologic, 2723 Immunology and Allergy, business, Adjuvant, 030215 immunology
Abstract

Since the introduction of allergen immunotherapy (AIT) over 100 years ago, focus has been on standardization of allergen extracts, with reliable molecular composition of allergens receiving the highest attention. While adjuvants play a major role in European AIT, they have been less well studied. In this Position Paper, we summarize current unmet needs of adjuvants in AIT citing current evidence. Four adjuvants are used in products marketed in Europe: aluminium hydroxide (Al(OH)(3)) is the most frequently used adjuvant, with microcrystalline tyrosine (MCT), monophosphoryl lipid A (MPLA) and calcium phosphate (CaP) used less frequently. Recent studies on humans, and using mouse models, have characterized in part the mechanisms of action of adjuvants on pre-existing immune responses. AIT differs from prophylactic vaccines that provoke immunity to infectious agents, as in allergy the patient is presensitized to the antigen. The intended mode of action of adjuvants is to simultaneously enhance the immunogenicity of the allergen, while precipitating the allergen at the injection site to reduce the risk of anaphylaxis. Contrasting immune effects are seen with different adjuvants. Aluminium hydroxide initially boosts Th2 responses, while the other adjuvants utilized in AIT redirect the Th2 immune response towards Th1 immunity. After varying lengths of time, each of the adjuvants supports tolerance. Further studies of the mechanisms of action of adjuvants may advise shorter treatment periods than the current three-to-five-year regimens, enhancing patient adherence. Improved lead compounds from the adjuvant pipeline are under development and are explored for their capacity to fill this unmet need.

Published
2020
Full Text
View/download PDF

7. Nasal specific IgE correlates to serum specific IgE: First steps towards nasal molecular allergy diagnostic

Author

Michael Gerstlauer, Karisa Thölken, Gertrud Hammel, Vera Schwierzeck, Mehmet Gökkaya, Stefanie Gilles, Stephan Knoch, and Claudia Traidl-Hoffmann

Subjects
Allergy, biology, Allergy Diagnosis, Ige, Pollen, Rhinitis, business.industry, Immunology, Rhinitis, Allergic, Seasonal, Allergens, Immunoglobulin E, medicine.disease, Rhinitis, Allergic, ddc, Nasal Mucosa, biology.protein, medicine, Humans, Immunology and Allergy, ddc:610, business, Serum specific ige
Published
2020
Full Text
View/download PDF

9. Unraveling the complexity of atopic dermatitis: The CK-CARE approach toward precision medicine

Author

Georg Schäppi, Cezmi A. Akdis, Peter Schmid-Grendlmeier, Claudia Traidl-Hoffmann, Thomas Bieber, and Roger Lauener

Subjects
medicine.medical_specialty, business.industry, Immunology, Eczema, Atopic dermatitis, Immunoglobulin E, Precision medicine, medicine.disease, Dermatology, ddc, Dermatitis, Atopic, Immunology and Allergy, Medicine, Humans, ddc:610, Precision Medicine, business, Atopic Dermatitis, Endotypes, Phenotype
Published
2020
Full Text
View/download PDF

10. Unexplained recurrent fever: when is autoinflammation the explanation?

Author

Tilmann Kallinich, Alexander A. Navarini, Clive Grattan, Eugen Feist, Helen J. Lachmann, H. D. de Koning, Marcus Maurer, Dan Lipsker, Karoline Krause, Claudia Traidl-Hoffmann, Marco Gattorno, and Anna Simon

Subjects
medicine.medical_specialty, Allergy, Fever, Immunology, Familial Mediterranean fever, Autoimmunity, Disease, Autoimmune Diseases, Diagnosis, Differential, medicine, Humans, Immunology and Allergy, ddc:610, Intensive care medicine, Inflammation, business.industry, Diagnostic test, Pathogenesis and modulation of inflammation Infection and autoimmunity [N4i 1], medicine.disease, Key features, Pathogenesis and modulation of inflammation [N4i 1], Recurrent fever, Disease Presentation, Generalized pustular psoriasis, business
Abstract

Item does not contain fulltext Recurrent fever can be the sole or leading manifestation of a variety of diseases including malignancies, autoimmune diseases and infections. Because the differential diagnoses are manifold, no formal guidelines for the approach of patients with recurrent fever exists. The newly recognized group of autoinflammatory diseases are often accompanied by repetitive fever attacks. As these episodes are frequently associated by a variety of divergent presentations, the differentiation of other causes for febrile illnesses can be difficult. In this article, we first review disease entities, which frequently present with the symptom of recurrent fever. In a next step, we summarize their characteristic pattern of disease presentation. Finally, we analyse key features of autoinflammatory diseases, which are helpful to distinguish this group of diseases from the other causes of recurrent fever. Recognizing these symptom patterns can provide the crucial clues and, thus, lead to the initiation of targeted specific diagnostic tests and therapies.

Published
2013
Full Text
View/download PDF

11. Erratum

Author

Patrick G. Holt, Stephen J. Galli, Carsten B. Schmidt-Weber, Georg Schäppi, Ulf Darsow, Ernst Rietschel, S. Hildemann, J. Ring, U. Mueller, H. zur Hausen, Ruby Pawankar, M. Akdis, S. T. Holgate, T. Bieber, Kurt Blaser, E. M. De Villiers, Jean Bousquet, Thomas A.E. Platts-Mills, Gianni Marone, Claudia Traidl-Hoffmann, Caroline Roduit, Judah A. Denburg, E. von Mutius, Bruce S. Bochner, C. Czerkinsky, Günther Menz, A. Jung, Roger Lauener, Ulrich Wahn, Cezmi A. Akdis, Martin Mempel, Thilo Jakob, John Bienenstock, Liam O'Mahony, Tari Haahtela, M. Kemeny, H. Koren, R. Lockey, Heidrun Behrendt, B. Menné, Adnan Custovic, Markus Ollert, Donald Y.M. Leung, Jeffrey M. Drazen, Reto Crameri, A. Fire, Harald Renz, O. de Beaumont, and W. Ammann

Subjects
0303 health sciences, Pediatrics, medicine.medical_specialty, Allergy, Clinical immunology, business.industry, Immunology, Declaration, Global problem, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, Family medicine, medicine, Immunology and Allergy, business, 030304 developmental biology
Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results